Effect of acetylsalicylic acid on aggregation of human platelets by Porphyromonas gingivalis

General Dentistry

Volumn 55, Issue 1, 2007, Pages 64-69

  Whitaker, Eugene J ^a   Thomas, Ian S ^d   Falk, Jessica A ^c   Obebe, Akindeko ^e   Hammond, Benjamin F ^b  

^a TEMPLE UNIVERSITY   (United States)

^b Department of Periodontal Microbiology   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; BACTERIAL COUNT; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DRUG EFFECT; HUMAN; IN VITRO STUDY; METHODOLOGY; PHYSIOLOGY; PORPHYROMONAS GINGIVALIS; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

ADENOSINE DIPHOSPHATE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; COLONY COUNT, MICROBIAL; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET-RICH PLASMA; PORPHYROMONAS GINGIVALIS;

EID: 33846627420     PISSN: 03636771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Beck JD, Offenbacher S. Oral health and systemic disease: Periodontitis and cardiovascular disease. J Dent Ed 1998;62:859-870.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1145.
3. Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost 2003;1:1897-1905.
4. Haffajee AD, Socransky SS. Microbial etiological agents of destructive periodontal diseases. Periodontol 2000 1994;5:78-111.
5. Lourbakos A, Yuan YP, Jenkins AL, Travis J, Andrade-Gordon P, Santulli R, Potempa J, Pike RN. Activation of protease-activated receptors by gingipains from Porphyromonas gingivalis leads to platelet aggregation: A new trait in microbial pathogenicity. Blood 2001;97:3790-3797.
6. Pham K, Feik D, Hammond BF, Rams TE, Whitaker EJ. Aggregation of human platelets by gingipain-R from Porphyromonas gingivalis cells and membrane vesicles. Platelets 2002;13:21-30.
7. Sharma A, Novak EK, Sojar HT, Swank RT, Kuramitsu HK, Genco RJ. Porphyromonas gingivalis platelet aggregation activity: Outer membrane vesicles are potent activators of murine platelets. Oral Microbiol Immunol 2000;15:393-396.
8. Naito M, Sakai E, Shi Y, Ideguchi H, Shoji M, Ohara N, Yamamoto K, Nakayama K. Porphyromonas gingivalis-induced platelet aggregation in plasma depends on Hgp44 adhesin but not Rgp proteinase. Mol Microbiology 2006;59;152-167.
9. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. New Engl J Med 2005;353:2373-2383.
10. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255-258.
11. McFarland J. Nephelometer: An instrument for estimating the number of bacteria in suspension used for calculating the opsonic index and for vaccines. J Am Med Assoc 1907;14:1176-1178.
12. Lzoesche WJ, Eklund S, Earnest R, Burt B. Longitudinal investigations of the role of Streptococcus sanguis in human fissure decay. Infect Immun 1979;26:498-507.
13. Evans G, Marian MB, Nishizawa EE, Mustard JF, Murphy EA. The effect of acetylsalicylic acid on platelet function. J Exp Med 1968;128:877-894.
14. Rao GH, Reddy RK, White JG. Low dose aspirin, platelet function and prostaglandin synthesis: Influence of epinephrine and alpha adrenergic blockade. Prostaglandins Med 1981;6:485-494.
15. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995;49:856-894.
16. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke. A case-crossover study. Stroke 2003;34:849-854.
17. Whitaker EJ, Pham K, Feik D, Rams TE, Barnett ML, Pan P. Effect of an essential oil-containing antiseptic mouthrinse on induction of platelet aggregation by oral bacteria in vitro. J Clin Periodontol 2000;27:370-373.
18. Otterdal K, Pedersen TM, Solum NO. Platelet shape change induced by the peptide YFLLRNP. Thromb Res 2001;103:411-420.
19. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Disc 2003;2:15-28.
20. Socransky SS, Haffajee AD. Implications of periodontal microbiology for the treatment of periodontal infections. Compend Suppl 1994;18:S684-S693.
21. Slots J, van Winkelhoff AJ. Antimicrobial therapy in periodontics. CDA J 1993;21:51-56.
22. Wu KK. Aspirin and other cyclooxygenase inhibitors: New therapeutic insights. Semin Vasc Med 2003;3:107-112.
23. Royzman D, Recio L, Badovinac RL, Fiorellini J, Goodson M, Howell H, Karimbux N. The effect of aspirin intake on bleeding on probing in patients with gingivitis. J Periodontol 2004;75:679-684.
24. Paquette DW, Williams RC, Offenbacher S, Beck JD. Long-term aspirin use and periodontitis: Cross-sectional human study. Abstract No. 1534, presented at 83rd General Session of IADR;Baltimore, MD:2005.
25. 2 as an amplifying signal for other agonists. Am J Cardiol 1991;68:118-158.
26. Wynn RL, Cook J. Does ibuprofen block the cardioprotective effects of aspirin in dental patients? General Dentistry 2006;54:6-9.
27. Parker RI, Gralnick HR. Effect of aspirin on platelet-von Willebrand factor surface expression on thrombin and ADP-stimulated platelets. Blood 1989;74:2016-2021.
28. Rasmussen UB, Gachet C, Schlesinger Y, Hanau D, Ohlmann P, Van Obberghen-Schilling E, Pouyssegur J, Cazenave JP, Pavirani A. A peptide ligand of the human thrombin receptor antagonizes-thrombin and partially activates platelets. J Biol Chem 1993;268:14322-14328.
29. Peerschke EI. Effect of epinephrine on fibrinogen receptor exposure by aspirin-treated platelets and platelets from concentrates in response to ADP and thrombin. Am J Hematol 1984;16:335-345.
30. Page RC, Schroeder HE. Pathogenesis of inflammatory periodontal disease. A summary of current work. Lab Invest 1976;33:235-249.
31. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: Emerging mechanistic paradigms. Circulation 1999;100:e20-28.